Palatin Announces FDA Clearance of IND Application for Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Phase 2 The clinical study is expected to begin in mid-2024 Organization of KOL virtual event “Beyond GLPs”. May 8, 2024 CRANBURY, NJ, May 2, 2024 /PRNewswire/ — Palatin Technologies, …